This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gottberg, K Articles by Fredrikson, S Search for Related Content PubMed PubMed Citation Articles by Gottberg, K Articles by Fredrikson, S Social Bookmarking                         What's this?

Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects

The MS Centre at Karolinska Institutet, Department of Neurology, Karolinska Institutet at Huddinge University Hospital, SE-141 86 Stockholm

A Gardulf

The Nursing Care Research and Development Unit at Huddinge University Hospital, SE-141 86 Stockholm, Sweden, The Department of Nursing Science, Karolinska Institutet, SE-171 77 Stockholm, Sweden

S Fredrikson

The MS Centre at Karolinska Institutet, Department of Neurology, Karolinska Institutet at Huddinge University Hospital, SE-141 86 Stockholm

The aims of this study were to investigate (i) the self-reported frequency and intensity of systemic side-effects and their impact on the daily lives of patients suffering from Multiple Sclerosis (MS) and undergoing interferon-beta therapy and (ii) the self-reported frequency and perceptions of any local-tissue reactions. Forty patients aged 22-59 years (27 females) with relapsing/remitting MS were consecutively recruited for the study (17 on interferon-beta-1a and 23 on interferon-beta-1b). Two self-administered questionnaires were used before and after 1, 4, 8 and 16 weeks of therapy. The interferon therapy was found to be associated with flu-like symptoms. Most systemic side-effects were reported to be mild and to have little impact on the patients' daily lives. Asthenia and fatigue were more often rated as moderate or severe. The most frequently reported local-tissue side-effects were redness and local pain at the injection sites. A considerable inter-individual variation was found among patients regarding the perceptions of both the systemic and local side-effects. This suggests that it is of importance to identify early those patients who may need more support or other interventions to maintain a successful compliance.

Key Words: multiple sclerosis • interferon-beta • side-effects • symptom occurrence • symptom distress • quality of life

Multiple Sclerosis, Vol. 6, No. 5, 349-354 (2000)
DOI: 10.1177/135245850000600510


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Mendozzi, F. Tronci, M. Garegnani, and L. Pugnetti Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study Multiple Sclerosis, February 1, 2010; 16(2): 238 - 247. [Abstract] [PDF]

				G Giovannoni, O Barbarash, F Casset-Semanaz, J King, L Metz, G Pardo, J Simsarian, P. Sorensen, B Stubinski, and on behalf of the Rebif(R) New Formulation Study Gr Safety and immunogenicity of a new formulation of interferon {beta}-1a (Rebif(R) New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results Multiple Sclerosis, February 1, 2009; 15(2): 219 - 228. [Abstract] [PDF]

				S Johansson, C Ytterberg, K Gottberg, L Widen Holmqvist, and L von Koch Use of health services in people with multiple sclerosis with and without fatigue Multiple Sclerosis, January 1, 2009; 15(1): 88 - 95. [Abstract] [PDF]

				S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]

				M. D Goldman, R. A. Marrie, and J. A Cohen Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls Multiple Sclerosis, April 1, 2008; 14(3): 383 - 390. [Abstract] [PDF]

				D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx Origin of Fatigue in Multiple Sclerosis: Review of the Literature Neurorehabil Neural Repair, February 1, 2008; 22(1): 91 - 100. [Abstract] [PDF]

				M. J. de Veer, M. Holko, M. Frevel, E. Walker, S. Der, J. M. Paranjape, R. H. Silverman, and B. R. G. Williams Functional classification of interferon-stimulated genes identified using microarrays J. Leukoc. Biol., June 1, 2001; 69(6): 912 - 920. [Abstract] [Full Text] [PDF]